Vertex Q3 revenue edges past estimates as full-year sales outlook rises

what happened

Vertex Pharmaceuticals said third-quarter revenue grew 12% year on year to $3.44 billion. According to LSEG data cited by Reuters, analysts had expected $3.42 billion. The gain came mainly from cystic fibrosis medicines, including the newly started ALYFTREK, along with higher realized prices and wider reimbursement in several countries.

Adjusted earnings per share were $4.76, below the $4.79 analysts forecast. Net income fell year on year, mainly because of costs tied to the Crinetics Pharmaceuticals acquisition, including compensation and transaction expenses. Sales of newer products such as CASGEVY, JOURNAVX and PALSONIFY also rose, which the company cited as evidence of diversification beyond cystic fibrosis.

Vertex now expects 2026 revenue of $13.15 billion to $13.25 billion, up from the earlier $13.1 billion to $13.2 billion range. It also expects CASGEVY and JOURNAVX to contribute $500 million or more in combined 2026 revenue.

why it matters

The key point for markets is the higher guidance, which signals that demand for cystic fibrosis treatments in the US remains strong. Weaker adjusted profit and deal-related costs temper the positive read. Investors will watch how the newer products grow and how the Crinetics deal affects margins in coming quarters.

market impact

Vertex shares: the raised outlook supports the stock, while the profit miss and deal costs weigh on it

• ↔Vertex shares mixed — the raised revenue outlook is offset by the adjusted EPS miss and acquisition costs

tags

instruments